An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer

Sponsor
Hoffmann-La Roche
Study ID
NCT01215123
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    Participants received bevacizumab according to routine clinical practice until disease progression, unacceptable toxicity or withdrawal, along with taxane-based chemotherapy or in combination with other chemotherapy as prescribed.

Study Details

This observational study will assess the median time of treatment duration and the safety of Avastin (bevacizumab) as first line treatment in patients with metastatic breast cancer. Data will be collected for approximately 24 months.

Key Dates

First listed
Oct 6, 2010
Start date
Jan 31, 2010
Status verified
Jan 2016
Primary completion
Jul 31, 2012
Completion
Jul 31, 2012

Study Design

Enrollment
28 participants (actual)

Arms

  • Arm: Bevacizumab
    Participants received bevacizumab according to routine clinical practice until disease progression, unacceptable toxicity or withdrawal, along with taxane-based chemotherapy or in combination with other chemotherapy as prescribed.

Primary Outcome Measure

Time to Disease Progression (TDP) [ Time Frame: Up to a maximum of 36.4 months ]

Related Studies